Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin
Therma Bright Inc. Provides Update on InStatin Development, Announcement of Key Strategic Advisor and Highlights Preclinical and IP Progress at InStatin
Therma Bright Inc. (TBRIF) reports significant progress in its InStatin subsidiary, which focuses on developing inhaled statin therapies for respiratory conditions. The company announced the appointment of Professor Sir Peter Barnes, a globally recognized respiratory expert, as a strategic advisor. Key developments include: (1) Completion of a rodent pharmacokinetic study to determine lung exposure duration with selected statins, (2) Dr. Amir Zeki receiving an NIH grant for conducting statin efficacy studies in monkeys using an ozone sensitization model, and (3) Engagement of Mike Rafa for IP development. InStatin's strategic focus on mild to moderate asthma treatment suggests a potentially faster regulatory approval pathway compared to the COPD market.
Therma Bright Inc. (TBRIF) annuncia importanti progressi nella sua controllata InStatin, specializzata nello sviluppo di terapie a base di statine inalate per patologie respiratorie. La società ha nominato Professor Sir Peter Barnes, esperto di fama mondiale nel campo delle malattie respiratorie, come consulente strategico. I principali sviluppi includono: (1) completamento di uno studio farmacocinetico su roditori per determinare la durata dell'esposizione polmonare alle statine selezionate, (2) il dottor Amir Zeki ha ottenuto una borsa di studio NIH per condurre studi sull'efficacia delle statine in scimmie utilizzando un modello di sensibilizzazione all'ozono, e (3) coinvolgimento di Mike Rafa per lo sviluppo della proprietà intellettuale. L'approccio strategico di InStatin, focalizzato sul trattamento dell'asma da lieve a moderato, suggerisce un possibile percorso di approvazione regolatoria più rapido rispetto al mercato della BPCO.
Therma Bright Inc. (TBRIF) informa de avances significativos en su subsidiaria InStatin, que se centra en el desarrollo de terapias con estatinas inhaladas para afecciones respiratorias. La compañía anunció el nombramiento del Profesor Sir Peter Barnes, experto respiratorio reconocido a nivel mundial, como asesor estratégico. Los desarrollos clave incluyen: (1) finalización de un estudio farmacocinético en roedores para determinar la duración de la exposición pulmonar con estatinas seleccionadas, (2) el Dr. Amir Zeki recibió una beca NIH para realizar estudios de eficacia de estatinas en monos utilizando un modelo de sensibilización con ozono, y (3) la incorporación de Mike Rafa para el desarrollo de propiedad intelectual. El enfoque estratégico de InStatin en el tratamiento del asma leve a moderado sugiere una vía de aprobación regulatoria potencialmente más rápida en comparación con el mercado de la EPOC.
Therma Bright Inc.(TBRIF)는 호흡기 질환을 위한 흡입용 스타틴 치료제 개발에 집중하는 자회사 InStatin에서 중요한 진전을 보고했습니다. 회사는 전 세계적으로 인정받는 호흡기 전문가인 Peter Barnes 경 교수를 전략 고문으로 임명했다고 발표했습니다. 주요 개발 사항은 다음과 같습니다: (1) 선택된 스타틴의 폐 노출 지속 시간을 확인하기 위한 설치류 약동학 연구 완료, (2) Dr. Amir Zeki가 오존 감작 모델을 이용한 원숭이 대상 스타틴 효능 연구를 위해 NIH 보조금을 수령, (3) 지적 재산권 개발을 위한 Mike Rafa 참여. InStatin의 경증에서 중등도 천식 치료에 대한 전략적 집중은 COPD 시장에 비해 규제 승인 절차가 더 빠를 가능성을 시사합니다.
Therma Bright Inc. (TBRIF) annonce des progrès significatifs au sein de sa filiale InStatin, spécialisée dans le développement de thérapies par statines inhalées pour les affections respiratoires. La société a nommé Professeur Sir Peter Barnes, expert respiratoire de renommée mondiale, en tant que conseiller stratégique. Les développements clés incluent : (1) la réalisation d'une étude pharmacocinétique chez des rongeurs pour déterminer la durée d'exposition pulmonaire aux statines sélectionnées, (2) le Dr Amir Zeki a obtenu une bourse NIH pour mener des études d'efficacité des statines chez les singes utilisant un modèle de sensibilisation à l'ozone, et (3) l'engagement de Mike Rafa pour le développement de la propriété intellectuelle. L'orientation stratégique d'InStatin vers le traitement de l'asthme léger à modéré suggère une voie d'approbation réglementaire potentiellement plus rapide comparée au marché de la BPCO.
Therma Bright Inc. (TBRIF) meldet bedeutende Fortschritte bei seiner Tochtergesellschaft InStatin, die sich auf die Entwicklung von inhalierten Statintherapien für Atemwegserkrankungen spezialisiert hat. Das Unternehmen gab die Ernennung von Professor Sir Peter Barnes, einem weltweit anerkannten Experten für Atemwegserkrankungen, als strategischen Berater bekannt. Wichtige Entwicklungen umfassen: (1) Abschluss einer pharmakokinetischen Studie an Nagetieren zur Bestimmung der Dauer der Lungenexposition bei ausgewählten Statinen, (2) Dr. Amir Zeki erhielt einen NIH-Zuschuss für Studien zur Wirksamkeit von Statinen bei Affen unter Verwendung eines Ozon-Sensibilisierungsmodells, und (3) Einbindung von Mike Rafa zur Entwicklung des geistigen Eigentums. Die strategische Ausrichtung von InStatin auf die Behandlung von leichtem bis mittelschwerem Asthma deutet auf einen potenziell schnelleren Zulassungsweg im Vergleich zum COPD-Markt hin.
Positive
Appointment of renowned respiratory expert Professor Sir Peter Barnes as strategic advisor
Successful completion of rodent pharmacokinetic study
Secured NIH grant for monkey efficacy studies
Strategic focus on mild to moderate asthma may enable faster regulatory pathway
Strengthening IP position through experienced patent consulting
Negative
Still in early preclinical stage with no human trials yet
Long pathway to commercialization ahead
Toronto, Ontario--(Newsfile Corp. - May 8, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on the significant progress achieved at InStatin over the past few months, focused on the development of inhaled statin therapies for respiratory conditions.
A key development at InStatin is the appointment of Professor Sir Peter Barnes as a strategic advisor. Sir Peter is a globally recognized respiratory clinician and innovative scientist renowned in the fields of asthma and Chronic Obstructive Pulmonary Disease (COPD). His extensive expertise and enthusiasm for inhaled statins align strongly with Therma Bright's vision for InStatin.
On the preclinical front, InStatin has successfully completed a rodent pharmacokinetic (PK) study to determine the duration of lung exposure with one of its selected statins. Furthermore, Dr. Amir Zeki has been awarded a significant grant from the National Institutes of Health (NIH) to conduct a crucial statin efficacy study in monkeys utilizing a well-established ozone sensitization model. The study will provide critical data on the therapeutic potential of InStatin's technology in a relevant preclinical model.
The well-established safety profile of statins and InStatin's initial focus on mild to moderate asthma is a strategic entry point, suggesting that regulatory approval in asthma may be a more expeditious pathway compared to the larger COPD market.
In parallel with its preclinical advancements, InStatin is actively strengthening its formulation and intellectual property (IP) position. The Company has engaged Mike Rafa of Rafa Patent Consulting, LLC, an experienced IP attorney, to support its IP development efforts.
Therma Bright is highly encouraged by the progress at InStatin, the invaluable addition of Professor Sir Peter Barnes as a strategic advisor, and the advancements in preclinical studies and IP development. InStatin remains committed to advancing towards clinical trials and realizing its potential to address significant unmet needs in the treatment of respiratory diseases.
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
FORWARD-LOOKING STATEMENTS Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as current and future development of InStatin and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Who is the new strategic advisor for Therma Bright's InStatin (TBRIF)?
Professor Sir Peter Barnes, a globally recognized respiratory clinician and innovative scientist renowned in asthma and COPD research, has been appointed as InStatin's strategic advisor.
What recent preclinical progress has Therma Bright (TBRIF) made with InStatin?
InStatin completed a rodent pharmacokinetic study and received an NIH grant for statin efficacy studies in monkeys using an ozone sensitization model.
What is InStatin's initial therapeutic focus for Therma Bright (TBRIF)?
InStatin is initially focusing on mild to moderate asthma treatment, which may offer a faster regulatory approval pathway compared to the COPD market.
How is Therma Bright (TBRIF) strengthening InStatin's intellectual property position?
The company has engaged Mike Rafa of Rafa Patent Consulting, LLC, an experienced IP attorney, to support its IP development efforts.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
